Nexstim (NXTMH:HEX, NXTMS:STO) is a targeted neuromodulation company developing and marketing pioneering, navigated, personalized, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD). A total of 31,202,364 shares were subscribed to, corresponding to 68.5 per cent of the total amount of the shares offered for subscription in the Offering. Subscriptions made in the Offering represent approximately 100.3 per cent of the Company’s market capital on 25 March 2019, the last trading day before announcement of the terms of the Offering. The proceeds of the Offering amount to approximately EUR 3.6 million.
Sisu Partners
Advised in the sale of
Nexstim Oyj
to